Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty‐Four of the GO‐VIBRANT Study

OBJECTIVE: To evaluate the safety and efficacy of intravenous (IV) golimumab treatment in psoriatic arthritis (PsA). METHODS: In this phase III, randomized, double‐blind, placebo‐controlled trial, patients were randomly assigned to receive IV placebo (n = 239) or golimumab at 2 mg/kg (n = 241) at we...

Descripción completa

Detalles Bibliográficos
Autores principales: Kavanaugh, Arthur, Husni, M. Elaine, Harrison, Diane D., Kim, Lilianne, Lo, Kim Hung, Leu, Jocelyn H., Hsia, Elizabeth C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765449/
https://www.ncbi.nlm.nih.gov/pubmed/28805045
http://dx.doi.org/10.1002/art.40226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765449/
https://www.ncbi.nlm.nih.gov/pubmed/28805045
http://dx.doi.org/10.1002/art.40226

Ejemplares similares